This activity has been designed to meet the educational needs of clinicians and non-clinicians involved in the care of patients with atopic dermatitis.
- Describe special considerations for managing adult and pediatric patients with AD under the threat of COVID-19
- Appraise strategies for improving access to care for adult and pediatric patients with AD under the threat of COVID-19
- Summarize the differential risk for viral infections among the systemic agents that are treatment options for MTSAD
Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
|Name of Faculty||Reported Financial Relationship|
|Lawrence Eichenfield, MD||
Consultant/Investigator: Novartis, Lilly, Regeneron, Sanofi/Genzyme, Dermira, Leo, AbbVie, Matrisys, Forte
|Hadar Lev-Tov, MD||
Speaker's Bureau: Society for Advanced Wound Healing
|Peter Lio, MD||
Advisory Board Member: Regeneron / Sanofi / Genzyme, Abbvie, Dermavant, Dermira, Eli Lilly, Galderma, Johnson & Johnson, L’Oreal, Theraplex, Unilever, IntraDerm and Realm Therapeutics
Consultant: Regeneron / Sanofi / Genzyme, Abbvie, AOBiome, Eli Lilly, Galderma, Johnson & Johnson, L’Oreal, Theraplex, Pierre-Fabre, Micreos, Pfizer
Speaker: Regeneron / Sanofi / Genzyme, Pfizer, Pierre-Fabre
Investigator: Regeneron / Sanofi / Genzyme, Abbvie, AOBiome
The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
|Name of Content Manager||Reported Financial Relationship|
|Venita Sivamani, Planner||LearnHealth founder and shareholder|
|Planners at Medical Education Resources||No financial relationships to disclose|
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and LearnHealth. MER is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This CE activity provides 1.0 contact hours of continuing nursing education.
Provider approved by the California Board of Registered Nursing, Provider Number 12299 for 1.0 contact hours.
Method of Participation
Participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each quiz question, and 4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better. Statements of credit will be available once the evaluation form is completed.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, LearnHealth, and Pfizer. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.